MSMB Capital Management (MSMB) has bid $378 million for biopharmaceutical company Amag Pharmaceuticals. The investment firm offered $18 a share in cash for the shares it does not already own in Lexington, Massachusetts-based Amag.
MSMB Capital, which owns 5% of Amag, opposes its proposed merger with Allos Therapeutics, adds Bloomberg. The all-stock combination between Amag and MSMB will value the merged business at $686 million.
Click here for the release from Business Wire.
Click here for additional coverage from Bloomberg.